Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$6.97M+16.8%-$8.37M+33.5%-$12.59M+38.1%-$20.34M+19.0%-$25.12M-8.7%
$197K-2.5%$202K+1.0%$200K0.0%$200K-9.1%$220K+14.6%
$11.97M-16.4%$14.31M+16.9%$12.24M+48.7%$8.23M+18.8%$6.93M-6.4%
-$24.65M-$29.39M-42.3%-$20.65M+6.9%
$5.82M-8.5%$6.36M+233%$1.91M+90.8%$1M+69.7%$590K+719%
-$58.56M-$4.74M+90.8%-$51.7M-48.0%-$34.94M+41.3%
$1.2M-47.9%$2.31M-9.8%$2.56M+31.3%$1.95M-98.6%$136.56M+4,566%
-$82.01M-216%$70.92M+341%$16.08M$80.97M+203%
-$30.47M-$30.39M-43.1%-$21.24M+4.6%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Tarsus Pharmaceuticals, Inc. generate?
Tarsus Pharmaceuticals, Inc. (TARS) generated -$96.9M in operating cash flow over the trailing twelve months.
What is Tarsus Pharmaceuticals, Inc.'s free cash flow?
After $15.1M of capital expenditures, Tarsus Pharmaceuticals, Inc.'s free cash flow was -$104.4M over the trailing twelve months, down 2.6% year over year.
Where does Tarsus Pharmaceuticals, Inc.'s cash flow data come from?
Every line is extracted from Tarsus Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.